Ohio State Navbar

Our Team

Graduate Research Associates


Emily McWilliams

Emily joined the lab in the spring of 2012 as a student in the Biomedical Sciences Graduate Program with an emphasis in immunology. She holds a B.S. degree in Chemistry from North Park University. She is a member of the Targeted Therapies group understanding the role of BAFF/BAFF-R in CLL as well as characterizing monoclonal antibody therapeutics to enhance B-cell depletion in combination with small molecule inhibitors. She is under the joint direction of Dr. Raj Muthusamy and Dr. John Byrd.

J.T. Greene

J.T. joined the lab in the summer of 2014 as a student in the Molecular, Cellular, and Developmental Biology graduate program at OSU. He holds a B.S. in Genetics, Cell Biology, and Development from the University of Minnesota. J.T. studies an apoptosis pathway in CLL to better understand its biology in hematological malignancies and search for potential drug targets. He is a member of the Targeted Therapies Group under the direction of Dr. Raj Muthusamy.

Shaneice Mitchell

Shaneice joined the lab in the Spring of 2013. She is a student in the Biomedical Sciences Graduate Program here at The Ohio State University.  Prior to joining the lab, Shaneice obtained a B.S. in Biochemistry with a minor in Microbiology from North Carolina State University.  Currently, her research focuses on the elucidation of PAK4 as a potential drug target in CLL and AML. She is conducting her research under the direction of Dr. Rosa Lapallombella and Dr. John Byrd.

Sean Reiff

Sean joined the lab in the spring of 2014 as a graduate fellow in the Medical Scientist Training Program. He holds B.S. degrees in Biology and Chemistry from Lee University. Sean matriculated to The Ohio State University College of Medicine in 2011 where he then joined the Biomedical Sciences Graduate Program with an emphasis in experimental therapeutics. He is a member of the Molecular Pharmacology group under the joint mentorship of Drs. Jen Woyach and John Byrd. Currently, Sean investigates BTK inhibitor therapies in CLL with the goal of circumventing resistance to ibrutinib.

Yo Ting Tsai MS

Yo-Ting joined the lab in the spring of 2012 as a student in the Medicinal Chemistry Program. Yo-Ting holds a B.S. in Life Science from the National Cheng-Hsing University and an M.S. in Pharmacology from the National Cheng-Kung University. She is a member of the Protein Metabolism group under the direction of Dr. David Lucas and Dr. John Byrd. She is currently working on the novel translational inhibitor Silvestrol which is being developed in collaboration with the National Cancer Institute.

Priscilla Do

Priscilla joined the lab in the spring of 2012 as a student in the Integrated Biomedical Sciences Graduate Program.  She holds a B.S. in Biochemistry from the University of Notre Dame. Currently, she is studying the role of the microenvironment in CLL under the joint direction of Dr. Raj Muthusamy and Dr. John Byrd.

Zachary Hing

Zach joined the lab in the spring of 2014. He is a student in the Medical Scientist Training Program (MD/PhD) at Ohio State. He holds a BS with distinction in chemistry from Duke University. His research focuses on the mechanisms underlying nuclear export and how they are deregulated in cancer. Translational components of his research aim to bring therapeutics targeting nuclear export to clinic to benefit patients with hematologic malignancies. He is under the direction of Drs. Rosa Lapalombella and John Byrd.

Eileen Hu

Eileen joined the lab in the summer of 2015 as a student in the Integrated Biomedical Sciences Graduate Program.  She holds a B.S. in Biochemistry from the University of California, Los Angeles. Currently, she is studying the role of the stem cells in CLL under the joint direction of Dr. Raj Muthusamy and Dr. John Byrd.

Timothy Chen

Tim joined the lab in the fall of 2013. He is a student in the Biomedical Scientist Graduate Program with an emphasis in genetics. He completed his undergraduate degree in Molecular Genetics  at the Ohio State University. His research focuses on understanding the role of NF-kB in  CLL and DLBCL, and targeting HSP90 as a therapy. Tim is co-mentored by Drs Erin Hertlein and John Byrd.

Chi-Ling Chiang (Nick) MS

Nick joined the lab in the summer of 2012 as a student of the Biomedical Sciences Graduate Program at The Ohio State University. He is a member of the Targeted Therapies Group under the direction of Dr. Raj Muthusamy. Nick is working on cancer-initiating stem cell and leukemogenesis in chronic lymphocytic leukemia (CLL) in two parts: 1. Identification of CLL developing mechanism relative to the hypothesis of leukemia stem cells and its malfunction. 2. Specific targeting delivery of small drug and microRNA by immunoliposomal nanoparticles for CLL.

Matthew Cannon

Matthew joined the lab in the spring of 2016 as a student in the Biomedical Sciences Graduate Program with an emphasis in experimental therapeutics and bioinformatics. He completed his undergraduate degree in Biochemistry at the Ohio State University. His current research focuses on uncovering the mechanisms of fetal hemoglobin repression in the treatment of Sickle Cell Disease, as well as investigating BRD4 as a target for CLL and DLBCL. He is pursuing this research under the direction of Drs. Rosa Lapalombella and John Byrd.

Shuai Dong MS

Shuai joined the lab in the spring 2013 as a student in the Pharmaceutics program. Shuai holds a B.S. in Pharmaceutical Sciences, an M.S. in Chemical Biology from Peking University and an M.S in Biomedical Science from University of Toledo. She is also a recipient of Pelotonia Graduate Fellowship and Eli Lily & Company Graduate Fellowship. She is a member of the Molecular Pharmacology group under the direction of Drs. Amy Johnson and John Byrd. Her work includes studying the role of PI3K p110 delta in CLL pathogenesis and in host immunity, and the role of SYK in AML pathogenesis.

Swagata Goswami MS

Swagata joined the lab in summer of 2016 as a student of Molecular, Cellular and Developmental Biology Graduate program at OSU.She has a BS in Microbiology from University of Calcutta and MS in Genetics from University of Delhi,  India. Swagata is working with Dr. Muthusamy, currently trying to develop the drug OSU-2s as a potential therapy in AML and identify it's targets.